Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-‘408, which is in a phase 1b trial for the treatment of vitiligo | Read More in JPost.com – Business & Innovation | The Jerusalem Post. in Israel NOWlej.
